Podcast: UK targets speedy clinical trial set-ups with 150-day benchmark
Faced with growing competition in the global clinical trials landscape, many countries are reforming regulatory frameworks in a bid to …
Post
-
-
ECO 2026: survodutide delivers renal and metabolic benefits in DKD model
At this year’s European Congress on Obesity (ECO), during a poster session, researchers presented an analysis of the effects of …
-
UK health secretary Wes Streeting resigns
UK health secretary Wes Streeting has resigned, citing a ‘loss of faith’ in the Labour party’s leadership under Prime Minister …
-
Shionogi weighs future of FXS drug after double Phase III miss
Shionogi is mulling over the fate of its fragile X syndrome (FXS) therapy, zatolmilast, after the drug failed to meet …
-
QuartzBio secures Eir Partners investment for trial intelligence platform
QuartzBio has secured a strategic investment and majority ownership from private equity company Eir Partners to expedite its clinical trial …
-
Osel and partners launch Phase IIb FLIP-2 trial of Lactin-V
Osel, Imperial College London’s clinical trials unit and March of Dimes have launched the Phase IIb FLIP-2 trial, assessing the …
-
Countries compete to reform trials in a bid to attract global sponsors
Clinical trial reforms have become abundant across the global pharmaceutical industry as regions look to stake their claim in attracting …
-
Trends in Renal Research: Nephrology’s Shift to Focus and Precision
Nephrology has long been a difficult space for drug development: trials were slow, complex, high cost, and often unrewarding, constrained …
-
New findings link common pesticide to early-onset colorectal cancer
The World Health Organization cites colorectal cancer (CRC) as the second leading cause of cancer-related deaths worldwide. Although it predominantly …
-
Novo Nordisk’s high-dose Wegovy touts near 28% weight loss in early responders
Novo Nordisk has shared new data that suggests a higher dose version of its blockbuster weight loss drug, Wegovy (semaglutide), …
-
Enterprise’s Phase II trial of ETD001 meets primary endpoint in pwCF
Enterprise Therapeutics (Enterprise) has announced that its Phase II clinical trial of ETD001, an investigational inhaled epithelial sodium channel (ENaC) …
-
Alkermes reports encouraging data from Phase III study of Lumryz
Alkermes has reported positive top line data from the Phase III REVITALYZ study, assessing the investigational use of extended-release Lumryz …
-
Makary resigns, with Diamantas named as acting FDA commissioner
Following news that started brewing last week, Dr Marty Makary has officially resigned from his post as commissioner of the …
-
Implementing AI in workflows: One step at a time
Artificial Intelligence (AI) is increasingly framed as a transformative tool that can address inefficiencies across therapeutic research and development (R&D). …
-
Despite turbulence at FDA, technical staff remain “dedicated,” says CMO
It has been a turbulent few months for the US Food and Drug Administration (FDA), with redundancies, leadership changes and …
